DRMA
Dermata Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.21
−1.63%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 1.6M | 2.9M | 8.2M | 4.1M | 5.7M |
| SG&A Expense | 4.6M | 4.8M | 4.3M | 4.0M | 4.0M |
| General & Admin Expense | 2.5M | — | — | 4.0M | 4.0M |
| Selling & Marketing Expense | 679.3K | — | — | — | — |
| Other Expenses | 2.4M | — | — | — | — |
| Total Operating Expenses | 8.6M | 7.8M | 12.5M | 8.0M | 9.7M |
| Cost and Expenses | 8.6M | 7.8M | 12.5M | 8.0M | 9.7M |
| Operating Income (EBIT) | (8.6M) | (7.8M) | (12.5M) | (8.0M) | (9.7M) |
| Non-Operating | |||||
| Interest Income | 232.4K | 215.0K | 225.8K | 247.2K | 63.6K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 232.4K | 215.0K | 225.8K | 247.2K | 63.6K |
| Other Non-Op Income/Expense | 232.4K | 215.0K | 225.8K | 247.2K | 63.6K |
| Non-Operating Income (excl Interest) | (115.2K) | — | (225.8K) | (247.0K) | — |
| EBT (Pre-Tax Income) | (8.4M) | (7.6M) | (12.3M) | (7.8M) | (9.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (8.4M) | (7.6M) | (12.3M) | (7.8M) | (9.6M) |
| Earnings from Cont. Ops | (8.4M) | (7.6M) | (12.3M) | (7.8M) | (9.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (8.4M) | (7.6M) | (12.3M) | (7.8M) | (9.6M) |
| Per Share | |||||
| Basic EPS | ($4.39) | ($8.16) | ($80.32) | ($401.80) | ($2,088.00) |
| Diluted EPS | ($4.39) | ($8.16) | ($80.32) | ($399.81) | ($2,088.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 4.0M | 926192 | 153000 | 19400 | 4604 |
| Diluted Shares Outstanding | 4.0M | 926192 | 153000 | 19496 | 4604 |
| Profitability Metrics | |||||
| EBITDA | (8.5M) | (7.8M) | (12.3M) | 247.2K | (9.7M) |
| D&A | — | — | — | 8.0M | — |
| EBIT | (8.5M) | (7.8M) | (12.3M) | (7.8M) | (9.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026